Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Lowered by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. reduced its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 64.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,016 shares of the biopharmaceutical company's stock after selling 48,249 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in Ultragenyx Pharmaceutical were worth $1,137,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Smartleaf Asset Management LLC boosted its holdings in Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 493 shares during the period. Human Investing LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $42,000. True Wealth Design LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the third quarter worth $43,000. Van ECK Associates Corp grew its holdings in Ultragenyx Pharmaceutical by 18.4% during the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 273 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at $83,000. Institutional investors and hedge funds own 97.67% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on RARE shares. Wells Fargo & Company upped their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research report on Friday, December 20th. Wedbush restated a "neutral" rating and set a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. HC Wainwright reaffirmed a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Canaccord Genuity Group raised their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. Finally, Piper Sandler dropped their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $91.71.

Remove Ads

Ultragenyx Pharmaceutical Trading Up 0.5 %

NASDAQ RARE traded up $0.18 during trading hours on Monday, reaching $39.36. The company's stock had a trading volume of 545,447 shares, compared to its average volume of 775,207. The business has a 50-day simple moving average of $41.88 and a 200 day simple moving average of $47.38. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37. The stock has a market cap of $3.64 billion, a PE ratio of -6.21 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. As a group, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Activity

In other news, CFO Howard Horn sold 1,785 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the sale, the chief financial officer now owns 106,169 shares of the company's stock, valued at approximately $4,289,227.60. The trade was a 1.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Emil D. Kakkis sold 11,727 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the transaction, the chief executive officer now directly owns 2,183,985 shares of the company's stock, valued at $92,229,686.55. This trade represents a 0.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 136,370 shares of company stock valued at $5,751,499. 5.80% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.